Overamping is a common problem among people who use stimulants

Robin Pollini at HR17. Photo by Liz Highleyman, hivandhepatitis.com

Overdosing on stimulants such as methamphetamine – known as 'overamping' – is an under-recognised problem in a harm reduction community that more often focuses on opioid overdose, according to a presentation yesterday at the 25th International Harm Reduction Conference (HR17) in Montréal.

The ongoing epidemic of overdoses due to prescription opioids, heroin or fentanyl is a well-known crisis, but stimulants can also be overused. While deaths due to heroin and fentanyl overdoses have risen sharply in recent years, stimulant-related mortality has seen a slower but steady rise, roughly doubling since 2010.

Opioid overdoses are usually characterised by potentially fatal respiratory depression, but overamping can involve a wide variety of inconsistent physical and mental symptoms, said Robin Pollini of the Pacific Institute for Research and Evaluation.

Glossary

harm reduction

Harm reduction is a set of practical strategies and ideas aimed at reducing negative consequences associated with drug use (including safer use, managed use and abstinence). It is also a movement for social justice built on a belief in, and respect for, the rights of people who use drugs.

anxiety

A feeling of unease, such as worry or fear, which can be mild or severe. Anxiety disorders are conditions in which anxiety dominates a person’s life or is experienced in particular situations.

stroke

An interruption of blood flow to the brain, caused by a broken or blocked blood vessel. A stroke results in sudden loss of brain function, such as loss of consciousness, paralysis, or changes in speech. Stroke is a medical emergency and can be life-threatening.

psychosis

Mental health problems that stop someone from thinking clearly and telling the difference between reality and their imagination.

depression

A mental health problem causing long-lasting low mood that interferes with everyday life.

Pollini and colleagues conducted a survey of people who inject drugs in Fresno, a city of 500,00 in California's inland Central Valley. Fresno has a very high rate of injection and non-injection drug use, but few services such as syringe exchange programmes.

The study included 494 participants. About 60% were men and most were either white (43%) or Latino (39%). The median age was 46 years and they had been injecting for 22 years on overage.

Study participants were asked about demographics, drug use, syringe access and injection behavior, overdoses, abscesses, use of drug treatment, and interactions with the criminal justice system. They were asked to describe what they know about HIV and hepatitis C virus (HCV) and received rapid HIV and HCV testing. The process took about three hours and participants were given $40 for their time.

Heroin was the most frequently used drug, both ever and in the past month (87% and 83%, respectively), followed by methamphetamine (76% and 60%). Many respondents reported using drugs in combination, including heroin plus methamphetamine (59% ever and 40% in the past month) and heroin plus cocaine or crack, known as a 'speedball' (59% and 23%, respectively). Use of prescription opioids or types of speed other than methamphetamine were relatively uncommon.

Participants were asked if they had experienced overamping or overdosing on stimulants such as methamphetamine or cocaine, described thusly:

"Here I’m using ‘overdose’ and ‘overamping’ interchangeably to mean a severe physical or mental health event that you experienced as a result of using stimulants. The physical health event might have been something like a heart attack, stroke, seizure or intense overheating that you believe was caused by taking stimulants. Mental health events might be extreme panic, paranoia, anxiety or agitation, hallucinations, or psychosis.”

More than a third of participants (192 or 39%) reported having ever experienced overamping or stimulant overdose, and 10% said they had done so in the past three months. Although more people had ever experienced an opioid overdose in the past, fewer did so in recent months (46% and 6%, respectively). The median number of both types of overdose episodes was three.

One in five participants said they had overdosed on both stimulants and opioids. More than three-quarters had used methamphetamine in the days leading up to their most recent overamping episode, but many also said they had used heroin (41%), cocaine or crack (20%) and other drugs (25%).

"These are not separate groups of people," Pollini emphasised.

Participants who reported overamping described a wide range of symptoms, having a median of nine:

  • Fast heart rate: 86%
  • Overheating: 76%
  • Extreme anxiety: 72%
  • Irregular breathing or shortness of breath: 71%
  • Panic: 68%
  • Hypervigilance: 67%
  • Extreme agitation: 64%
  • Extreme paranoia: 51%
  • Falling asleep or passing out: 46%
  • Chest pain or tightness: 44%
  • Nausea or vomiting: 43%
  • Hallucinations: 40%
  • Jerking or rigid limbs: 34%
  • Vision symptoms such as tunnel vision or eyes twitching: 25%
  • Feeling paralysed while awake: 26%
  • Seizures or convulsions: 17%
  • Feeling like they were having a stroke: 6%

Usually someone else was present during an overamping episode, most often a friend, partner or spouse. But 27% were alone when it happened.

The wide variety of symptoms, which overlap with many other conditions, make it difficult to identify overamping, and people often do not know when to call for emergency services or go to an emergency department, Pollini said.

About a quarter of study participants said they had gone to an emergency room when they experienced overamping, and 14% ended up being admitted to a hospital. In addition, 18% said that an ambulance was summoned and 12% said the police came.

"Harm reduction programs where stimulant use is common should consider expanding overdose education efforts to include overamping risk reduction, identification, and response," the researchers concluded. "Many people who inject drugs in our study reported both stimulant and heroin use on the day of their last overamping event, suggesting that combining education on opioid and stimulant overdose may be appropriate."

Pollini acknowledged, however, that not only are the symptoms of overamping inconsistent and not well recognised, but it is also unclear what the risk factors are, how to prevent it, and how best to respond.

Currently there is no known way to reverse a stimulant overdose, as naloxone does for an opioid overdose. Speaking at a press briefing with Pollini, Dan Ciccarone of the University of California San Francisco said that a colleague has been evaluating candidates for use as a safer methamphetamine substitution therapy, but all trials have been negative so far.

References

Pollini R, et al. "Overamping" – an understudied overdose experience among people who inject drugs. 25th International Harm Reduction Conference, Montréal, abstract 518, 2017.

View the abstract on the conference website.